Tipifarnib，又称替吡法尼，是可口服的farnesyltransferase (FTase)抑制剂，在多种H-ras或N-ras突变细胞中表现出抗增殖作用，具有抗肿瘤活性。

参考文献

[1] Puntambekar DS, Giridhar R, Yadav MR. Inhibition of farnesyltransferase: a rational approach to treat cancer? J Enzyme Inhib Med Chem. 2007 Apr;22(2):127-40. doi: 10.1080/14756360601072841(IF:4.027).

[2] Bai F, Villagra AV, Zou J, et al. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immunother. 2012 Apr;61(4):523-33. doi: 10.1007/s00262-011-1109-0(IF:4.90).

[3] Martin LA, Head JE, Pancholi S, et al. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol Cancer Ther. 2007 Sep;6(9):2458-67. doi: 10.1158/1535-7163.MCT-06-0452(IF:4.856).

-25~-15℃保存，有效期3年。